Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S P Ivy

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
British Journal of Cancer|June 9, 2005
Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodarP M Fracasso, K A Blum, M K Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancerJ F Liu, W T Barry, M Birrer, et al.
British Journal of Cancer|July 23, 2013
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)S Sahebjam, P L Bedard, V Castonguay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancerA G Waks, O Cohen, B Kochupurakkal, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
British Journal of Cancer|June 9, 2005
Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodarP M Fracasso, K A Blum, M K Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancerJ F Liu, W T Barry, M Birrer, et al.
British Journal of Cancer|July 23, 2013
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)S Sahebjam, P L Bedard, V Castonguay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 5, 2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancerA G Waks, O Cohen, B Kochupurakkal, et al.
Pageof 3